Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Eagle Pharmaceuticals Inc EGRX

Healthcare Biotechnology
Eagle Pharmaceuticals, Inc. is a fully integrated pharmaceutical company with research and development, clinical, manufacturing and commercial capabilities. The Company is focused on developing medicines that result in improvements in patients' lives. The Company's commercialized products include vasopressin, PEMFEXY, RYANODEX, BENDEKA, BELRAPZO, TREAKISYM (Japan), and BYFAVO and BARHEMSYS... see more

Recent & Breaking News (GREY:EGRX)

Shareholders that lost money on Eagle Pharmaceuticals, Inc. (EGRX) Urged to Join Class Action - Contact Levi & Korsinsky to Learn More

Accesswire February 8, 2024

Class Action Filed Against Eagle Pharmaceuticals, Inc. (EGRX) - February 9, 2024 Deadline to Join - Contact Levi & Korsinsky

Accesswire February 8, 2024

EGRX Investors Have Opportunity to Lead Eagle Pharmaceuticals, Inc. Securities Fraud Lawsuit

PR Newswire February 8, 2024

Levi & Korsinsky Notifies Shareholders of Eagle Pharmaceuticals, Inc.(EGRX) of a Class Action Lawsuit and an Upcoming Deadline

Accesswire February 8, 2024

The Law Offices of Frank R. Cruz Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Eagle Pharmaceuticals, Inc. (EGRX)

Business Wire February 8, 2024

Shareholders that lost money on Eagle Pharmaceuticals, Inc.(EGRX) should contact Levi & Korsinsky about pending Class Action - EGRX

Accesswire February 8, 2024

DEADLINE TOMORROW: The Schall Law Firm Encourages Investors in Eagle Pharmaceuticals, Inc. with Losses of $100,000 to Contact the Firm

Newsfile February 8, 2024

Class Action Filed Against Eagle Pharmaceuticals, Inc. (EGRX) Seeking Recovery for Investors - Contact Levi & Korsinsky

Accesswire February 8, 2024

EGRX LAWSUIT ALERT: Levi & Korsinsky Notifies Eagle Pharmaceuticals, Inc. Investors of a Class Action Lawsuit and Upcoming Deadline

Accesswire February 8, 2024

EGRX FINAL DEADLINE: Bronstein, Gewirtz & Grossman LLC Reminds Eagle Pharmaceuticals, Inc. Shareholders of Final Hours to Join Class Action!

Accesswire February 8, 2024

SHAREHOLDER ALERT: The Law Offices of Vincent Wong Remind Eagle Pharmaceuticals Investors of a Lead Plaintiff Deadline of February 9, 2024

PR Newswire February 8, 2024

Levi & Korsinsky Reminds Shareholders of a Lead Plaintiff Deadline of February 9, 2024 in Eagle Pharmaceuticals Lawsuit - EGRX

Accesswire February 8, 2024

Levi & Korsinsky Announces the Filing of a Securities Class Action on Behalf of Eagle Pharmaceuticals, Inc.(EGRX) Shareholders

Accesswire February 8, 2024

FINAL DEADLINE FRIDAY: The Schall Law Firm Encourages Investors in Eagle Pharmaceuticals, Inc. with Losses of $100,000 to Contact the Firm

Accesswire February 8, 2024

Eagle Pharmaceuticals Shareholder Notice

Newsfile February 7, 2024

Class Action Filed Against Eagle Pharmaceuticals, Inc. (EGRX) Seeking Recovery for Investors - Contact Levi & Korsinsky

Accesswire February 7, 2024

EGRX 2-DAY DEADLINE ALERT: Hagens Berman, National Trial Attorneys, Encourages Eagle Pharmaceuticals (EGRX) Investors with Substantial Losses to Contact Firm Before Feb. 9th Deadline in Securities Fraud Class Action

Accesswire February 7, 2024

SHAREHOLDER ALERT: Pomerantz Law Firm Announces the Filing of a Class Action Against Eagle Pharmaceuticals, Inc. - EGRX

PR Newswire February 7, 2024

Levi & Korsinsky Reminds Eagle Pharmaceuticals Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of February 9, 2024 - EGRX

Accesswire February 7, 2024

FRIDAY DEADLINE NOTICE: The Schall Law Firm Encourages Investors in Eagle Pharmaceuticals, Inc. with Losses of $100,000 to Contact the Firm

Newsfile February 7, 2024
USER FEEDBACK SURVEY ×

Be the voice that helps shape the content on site!

At Stockhouse, we’re committed to delivering content that matters to you. Your insights are key in shaping our strategy. Take a few minutes to share your feedback and help influence what you see on our site!

The Market Online in partnership with Stockhouse
Later
Participate
Not interested